Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo

Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo–control study

Published:2019-08-17 Issue:12 Volume:44 Page:2112-2118
ISSN:0893-133X
Container-title:Neuropsychopharmacology
language:en
Short-container-title:Neuropsychopharmacol.

Author:

Chen Mu-Hong^ORCID,Cheng Chih-Ming^ORCID,Gueorguieva Ralitza,Lin Wei-Chen,Li Cheng-Ta,Hong Chen-Jee,Tu Pei-Chi,Bai Ya-Mei,Tsai Shih-Jen^ORCID,Krystal John H.,Su Tung-Ping

Publisher

Springer Science and Business Media LLC

Subject

Psychiatry and Mental health,Pharmacology

Link

http://www.nature.com/articles/s41386-019-0480-y.pdf

Reference36 articles.

1. Howland RH. Sequenced treatment alternatives to relieve depression (STAR*D). Part 2: study outcomes. J Psychosoc Nurs Ment health Serv. 2008;46:21–4.

2. Gitlin M. Treatment-resistant bipolar disorder. Mol Psychiatry. 2006;11:227–40.

3. Schoeyen HK, Kessler U, Andreassen OA, Auestad BH, Bergsholm P, Malt UF, et al. Treatment-resistant bipolar depression: a randomized controlled trial of electroconvulsive therapy versus algorithm-based pharmacological treatment. Am J Psychiatry. 2015;172:41–51.

4. Poon SH, Sim K, Sum MY, Kuswanto CN, Baldessarini RJ. Evidence-based options for treatment-resistant adult bipolar disorder patients. Bipolar Disord. 2012;14:573–84.

5. Al-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012;6:369–88.

Cited by 54 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treat bipolar depression with atypical antipsychotics and mood stabilisers; new therapies require further study;Drugs & Therapy Perspectives;2024-03

2. Clinical Trials Studying Suicide Risk Reduction: Who is Excluded From Participation;Archives of Suicide Research;2024-02-28

3. d-Cycloserine enhances the bidirectional range of NMDAR-dependent hippocampal synaptic plasticity;Translational Psychiatry;2024-01-09

4. A systematic review of the incidence of medical serious adverse events in sub-anesthetic ketamine treatment of psychiatric disorders;Journal of Affective Disorders;2024-01

5. Targeting NMDAR/AMPAR: a promising pharmacotherapeutic approach for depressive disorders;S.S. Korsakov Journal of Neurology and Psychiatry;2024